

Europäisches Patentamt
Europ an Pat nt Offic
Office eur péen des brevets



(11) **EP 1 138 323 A2**

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
04.10.2001 Bulletin 2001/40

(51) Int Cl.7: **A61K 31/047**, A61K 9/06,
A61P 17/00, A61P 17/06,
A61P 17/10

(21) Application number: **01106638.8**

(22) Date of filing: **16.03.2001**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **24.03.2000 IT MI000630**

(71) Applicants:
• **D.B.P. (Development Biotechnological Processes) di Rossi Valentina e C. s.n.c.**
83100 Avellino (IT)
• **Nuova ICT s.r.l.**
26845 Codogno (Lodi) (IT)

(72) Inventors:
• **Pelliccia, Maria Teresa**
83100 Avellino (IT)
• **Giannella, Attilio**
26845 Codogno (Lodi) (IT)
• **Giannella, Jenny**
26845 Codogno (Lodi) (IT)

(74) Representative: **Minoja, Fabrizio, Dr.**
Bianchetti Bracco Minoja S.r.l.
Via Rossini, 8
20122 Milano (IT)

(54) **Resveratrol for the treatment of exfoliative eczema, acne or psoriasis**

(57) The use of resveratrol (3,4',5-trihydroxy-trans-stilbene) and derivatives thereof, for the preparation of medicaments for the treatment of exfoliative eczema, acne and psoriasis, topical pharmaceutical formulations containing resveratrol or derivatives thereof in combination with other active principles. Treatment consists in topical administrations of resveratrol at concentrations

of 0.01 to 20%, in the form of lotions, creams or ointments, optionally in combination with other active principles such as melatonin, vitamins D, E and A and derivatives thereof, hormones, vegetable and/or animal extracts. Contrary to current therapies, the use of resveratrol has neither systemic nor topical effects during and after therapy.

EP 1 138 323 A2

BEST AVAILABLE COPY

Description

[0001] The present invention relates to the use of resveratrol (3,4',5-trihydroxy-trans-stilbene) and derivatives thereof (esters, glycosides, 3'-oxyresveratrol), for the preparation of medicaments for the treatment of exfoliative eczema, acne and psoriasis.

[0002] Resveratrol (3,4',5-trihydroxy-trans-stilbene), a phytoalexin produced by a number of vegetables under stress conditions, is one of the natural substances of vegetable origin at present arousing great interest in the pharmaceutical, cosmetic and nutritional fields, due to the important, established effects this molecule exerts in humans.

[0003] In vitro and in vivo studies on resveratrol proved that the molecule: a) exerts protective action on the cardiovascular system, (Clin. Chim. Acta, 235:207, 1995) and decreases arteriosclerosis risks (Clin. Chim. Acta, 246:163, 1996); b) has vasal relaxing effect on the arteries (Gen. Pharm. 27:363, 1996); c) has antioxidant action which inhibits LDL cholesterol peroxidation (The Lancet, 341: 1103, 1993); reduces oxidative stress (Neuroreport 8:1499, 1997); protects from the radical damage in cerebral ischemia (Chin. Pharm. Bull. 12: 128, 1996); prevents the propagation of free radicals responsible for the molecular damage of the biological systems and for cell aging; d) modulates lipid synthesis, preventing the accumulation of cholesterol and fats in the liver, decreases the concentrations of blood triglycerids and of cholesterol in low-density LDL lipoproteins and reduces the atherogenic index (Chem Pharm. Bull. 30:1766, 1982); e) inhibits platelet aggregation, preventing the formation of thrombi (Int. J. Tiss. Reac. XVIII, 1, 1995; Thrombosis and Haemostasis, 76: 818, 1996); f) inhibits the production of pro-atherogenic eicosanoids by platelets and neutrophils, exerting anti-inflammatory action (Biochem. Biophys. Acta, 834:275, 1985); g) inhibits protein-tyrosine kinase which modulates cell proliferation and differentiation and the signaling processes in the immune system cells, biological processes involved in the inflammatory response and in severe pathologies such as cancer, arteriosclerosis and psoriasis (J. Natural Products, 56:1805, 1993, Science 267: 1782, 1995); h) has marked antimutagenic action, inhibiting the cell events connected with the initiation, promotion and progression of the tumor (Science 275:218, 1997, Anal. Biochem, 169:328, 1988, Proc. Natl. Acad. Sci USA, 91:3147, 1994, Proc. Natl. Acad. USA, 72: 1848, 1975, Carcinogenesis, 8:541, 1987). The presence of resveratrol traces in red wines is believed to be the main cause of the beneficial nutritional effects thereof (Am. J. Enol. Vitic. 46:159, 1996, Clin. Chim. Acta, 246:183, 1996, Amer. J. Clin. Nutr., 55:1012, 1992). The poor concentrations of resveratrol in wine and in wine industry by-products have, until some time ago, remarkably restricted a wide use of this molecule in the pharmaceutical and nutritional fields. Recently, rhizomes of the Chinese plant *Poligonum cuspidatum* have been

found to contain high amounts of resveratrol (more than about 400 times those in wine) thus inducing a strong commercial development of this molecule as alimentary supplement, in particular on the U.S. market. Lately, the actions of resveratrol for pharmacological or cosmetic use have been claimed (WO9959561; WO9958119; EP0773020; FR2766176; WO9904747).

[0004] It has now been found that resveratrol can be effectively used in the treatment of exfoliative eczema, acne, psoriasis lesions and all the exfoliative skin diseases. The treatment according to the invention consists in the topical administration of resveratrol at concentrations of 0.01 to 20%, preferably of 1 to 5%, in the form of lotions, creams or ointments, also in combination with other active principles such as melatonin, vitamins D, E and A or derivatives thereof, hormones, vegetable and/or animal extracts, azadirachtin, retinoic acid or derivatives thereof, methotrexate or derivatives thereof, cyclosporin or derivatives thereof, palladium and/or ruthenium or derivatives thereof, immunosuppressors, anti-inflammatory agents, phototherapeutics and cell hyperproliferation modulators.

[0005] Particularly preferred are the combinations with vitamin D derivatives and with corticoids for the topical treatment of psoriasis, and with vitamin A for the treatment of skin dystrophic forms possibly associated with scaling.

[0006] Contrary to the current therapies, the use of resveratrol induces neither systemic nor topical effects during and after the treatment. Furthermore, no changes of neutrophils activity, of circulating cells or of cells at the lesion site, were observed after topical treatment with resveratrol. Therefore, the therapeutical action of resveratrol cannot be ascribed at all to an already known action mechanism connected with the neutrophil component (Biochem. Biophys. Acta, 834:275, 1985).

[0007] As a consequence, none of the well-known above described properties of resveratrol can explain the effectiveness of the molecule in the treatments of exfoliative eczema, acne, psoriasis and generally all exfoliative skin diseases, which is the object of the present application.

[0008] Therefore, none available knowledge of resveratrol could suggest its usefulness in the treatment of the diseases according to the invention. In particular, WO9959561 (Hensley et al.) considers the action on neutrophils, particularly on the enzyme myeloperoxidase, the therapeutical basis of the use of resveratrol in a series of diseases, inter alia psoriasis itself. As a matter of fact, psoriasis pathogenesis is much more complex and cannot at all be ascribed to the only action of neutrophils, or even more simplistically to the activation of a single enzyme, myeloperoxidase, produced by said cells. On the other hand, the involvement of various types of cells, either immunocompetent or not, in psoriasis is widely established (Nature Medicine 5, 442, 1995; J. Invest. Dermatol. 101, 695, 1993; J. Invest. Dermatol. 102, 145, 1994) and the treatments used to date

act on both the immunologic and keratinocyte components.

[0009] Current treatments for some of the pathologies for which the topical use of resveratrol is proposed, as well as the limits thereof, are summarized in the following.

EXFOLIATIVE ECZEMA

[0010] Exfoliative eczema is a skin inflammation characterized by redness, itching and oozing, sometime scaling, lesions. As for the etiology, family history of atopy is frequent (Journal of Allergy and Clinical Immunology, 13, 487-494, 1986). In any event, the development of said skin allergic sensitivity definitely involves environmental triggering factors. In 1988 some researchers have identified a significant connection between atopy and chromosome 11q13 (Lancet 1, 1292-1295, 1988). The treatment of exfoliative eczema may be extremely demanding and the severity of symptoms, the age of the patient, the affected body site and any other worsening factors should be considered. No treatment exists which can ease symptoms in all of the treated patients. To date, most therapies, either the topical and/or systemic ones, may involve remarkable side effects thus making it necessary to stop treatment. Topical treatment of exfoliative eczema comprises the use of emollients, steroids (which can induce atrophy and depigmentation of the skin as well as iatrogenic Cushing's syndrome in case of systemic absorption) and topical or systemic immunosuppressors (cyclosporin, FK-506 or other similar drugs inducing severe side effects). Furthermore, a number of studies proved the beneficial effect of ultraviolet radiations in the treatment of exfoliative eczema. Exposure to UV rays, however, involves risks of development of skin cancer and should therefore be considered a last resort.

ACNE

[0011] Acne is a disease of the pilosebaceous follicle connected with disfunctions of the sebaceous gland. Development from sebum overproduction to acne takes place when in sebaceous follicles, which have a large sebaceous gland and a thin hair, hyperkeratosis of the hair follicle infrainfundibular portion occurs, most likely following an irritant stimulus on the infrainfundibular keratinic cells. This leads to blockage of the sebaceous follicle, thus preventing sebum discharge. These conditions are extremely favorable to the growth of some bacteria, such as *Propionibacterium acnes*. The increase in the sebum mass, causes dilation and rupture of the follicle with the release of its contents into the dermal tissue, with severe inflammation. As a consequence appear the typical acne lesions: papules, pustules and, in the more serious cases, nodules and cysts. The therapeutical approach should take into consideration the severity of the process, the polymorphism of the lesions

as well as the complex etiology of the disorder. Substances currently available for the topical or systemic treatment of acne (benzoyl peroxide, retinoic acid, azelaic acid, oral antibiotics, anti-androgens) can, involve remarkable side effects, so that occasionally treatment must be discontinued.

PSORIASIS

[0012] Psoriasis is a common inflammatory disease of the skin characterized by excessive scaling, which affects about 2% of the population (Cristophers, E, and Sterry W, 1993. Psoriasis. In Dermatology in General Medicine. T.B. Fitzpatrick et al editors. McGraw-Hill, New-York, 489-514). Etiology is still unknown, and the primary cause could be due either to abnormal keratinocytes function or to inflammatory-immune disorders. Psoriasis varies in type and severity and can affect different body areas. Current therapies can be topical and/or systemic, but all of them involve remarkable side effects which can induce discontinuation of the treatment. Topical treatments with mineral coaltar (which has unpleasant smell, uncertain effectiveness and induces photosensitization), with steroids (whose topical and systemic side effects are well known), vitamins D3 and retinoids (which can cause photosensitization and are teratogenic) have been proposed. Furthermore, treatment with ultraviolet radiation optionally combined with the administration of psoralenes has been suggested. Drugs used for the systemic therapy of psoriasis comprise: methotrexate, cyclosporin and other immunosuppressors, oligoelements such as palladium or red ruthenium and antiproliferative drugs, all of them having un-negligible toxic potential.

[0013] The invention is described in further detail in the following.

Example 1 - Exfoliative eczema

[0014] Experiments were carried out on patients (n=20) of both sexes, of age above 18 years, suffering from severe disabling exfoliative eczema unresponsive to the current topical treatments.

[0015] All patients were subjected to complete blood count and measurements of renal and hepatic functions prior to treatment. Patients who had been systemically treated two months previously with corticoids, antibiotics, psoralenes and other immunosuppressants or with UV were excluded. Patients were supposed not to use any corticoid topically.

[0016] Treatment - Out of 20 patients, 10 were included in the resveratrol-treated group (1% resveratrol ointment) and 10 in the control group (ointment with no resveratrol). The two groups were comparable as for sex, age, duration and severity of the eczema. Patients were divided in two groups and treated twice a day for six months either with the resveratrol-containing ointment or with the placebo ointment (control group).

[0017] Evaluations - The progress of the disease was monitored by using the "six-area/six-sign score" method. The severity of the six signs used for monitoring the disease (erythema, pustules, excoriations, dehydration, scaling of the skin and lichenification), was evaluated on a 0-3 score (none, mean, moderate and severe), in each of the six body areas tested (head, neck, hands, elbows, feet, legs and trunk). The severity of itching and of sleep disorders was evaluated on a 0-3 score (none, mean, moderate and severe).

[0018] Results - Only in the resveratrol-treated subjects the mean of the values concerning the different clinical symptoms considered rapidly decreased from 57.0 (SEM 1.6 n=10) to 21.5 during the first two weeks of treatment. At the end of the treatment the 8 resveratrol-treated patients showed significant improvements of all the considered parameters, whereas two of them only showed improvements concerning skin scaling. No control subjects showed recovery signs. At the beginning of the treatment, the body area affected by eczema was 69% on the average in all patients. This gradually decreased during treatment, to reach 27% only in the resveratrol-treated patients. At the end of the treatment, the mean scores for itching decreased from 2.3 to 0.6 and for sleep disorders from 2.9 to 1.0. only in the resveratrol-treated patients.

Example 2 - Acne

[0019] A randomized, double blind study was carried out in order to evaluate the effectiveness of topical administration of resveratrol in the treatment of acne vulgaris. Patients (n=30) of 15 to 19 years were all suffering from II or III degree acne (according to Pillsbury's classification), with multiple inflammatory lesions (20 to 62) and a number of comedos (28 to 120) on face and forehead. Only subjects who had received no systemic treatment with antibiotics for at least 4 weeks and had used no topical medicaments for 2 weeks before treatment were selected. During treatment with resveratrol, no further topical treatment was allowed. The effectiveness of the therapy was evaluated by comparing the conditions of the lesions before and after the treatment, according to an arbitrary score of 0 to 5 (0=worsening; 1=no changes; 2=slight improvement; 3=modest improvement; 4=good improvement; 5=excellent improvement).

[0020] Treatment - Treatment consisted of daily topical administrations of resveratrol (1% cream) or of the carrier only, for 10 weeks in 30 patients suffering from acne vulgaris. The evaluated parameters were: number of acne lesions and comedos, erythema, seborrheic skin and skin scaling.

[0021] Results - Patients treated with resveratrol showed neither systemic nor topical side effects. A significant reduction of erythema, number of acne lesions, comedos and, above all, scaling, was observed in treated subjects (96%), compared with control subjects

(2%). More particularly, the effectiveness of the treatment in 95% of cases proved to be due to the reduction of follicle hyperkeratosis, which is an important factor in the formation of comedos since it causes thickening of the follicle wall with sebum retention.

Example 3 - Psoriasis

[0022] A prospective, multi-center, double blind study was effected on patients of both sexes, of age above 18 years, with a clinical diagnosis of mild to moderate chronic psoriasis, with affected areas of at least 100 cm², but not above 40% of the total body area. Patients with pustular psoriasis or with psoriasis guttata, those who had received either topical treatment for two weeks before the test or systemic treatment in the 8 weeks before the test, as well as pregnant and nursing women or patients receiving more than 400 IU of vitamin D daily or any other medicament potentially affecting the progress of the disease, were excluded.

[0023] Treatment - Out of 48 patients, 12 were included in the resveratrol-treated group (1% resveratrol ointment), 12 in the control group (ointment with no resveratrol), 12 in a group treated with a Vitamin D derivative (calcipotriol 50 mg/g) and 12 in a group treated with the combination resveratrol/Vitamin D derivative (1% resveratrol/ 50 mg/g calcipotriol). The 4 groups were comparable as for sex, age, duration and severity of psoriasis: Patients were treated twice a day for one month with the different ointments.

[0024] Evaluations - At the end of the treatment, the clinical response was evaluated as "healed", "marked improvement", "slight improvement", "no changes", "worsening". Quality life evaluations were carried out before and after the treatment, by using the "psoriasis Disability Index" (PDI) and the "Sickness Impact Profile" (SIP). The PDI questionnaire included 15 questions as follows: daily activities (5 questions), work or school, if applicable, (3 questions), personal relationships, (2 questions), spare time (4 questions), treatment, (1 question). Each question had a 1 to 7 score. The purpose of said questions was to evaluate symptoms and feelings of the patients concerning their psoriasis during the first 4 weeks of treatment.

[0025] Clinical effectiveness - At the end of the treatment, the percentages of patients healed or showing marked improvement were 80% for those treated with resveratrol and 10% for the control group. Effectiveness of the treatment with Vitamin D derivatives was observed only in 47% of the patients, whereas the Vitamin D derivatives / resveratrol combination was effective in 95% of patients.

[0026] Life quality of the patients, as evaluated by PDI, increased only after treatment with resveratrol. The reduction in the total PDI score was 6.5 in the resveratrol group (95% CI 4.4, 8.6; P=0.001) and 1.7 in the control group (95% CI 1.1, 6.3; P= 0.005).

Claims

1. The use of resveratrol or derivatives thereof for the preparation of medicaments for the treatment of exfoliative eczema and hyperkeratosis disorders.
2. The use of resveratrol or derivatives thereof for the preparation of medicaments for the treatment of acne.
3. The use of resveratrol or derivatives thereof for the preparation of medicaments for the treatment of psoriasis.
4. Topical pharmaceutical formulations containing resveratrol or derivatives thereof in combination with melatonin, vitamins D, E and A or derivatives thereof, hormones, vegetable and/or animal extracts, azadirachtin, retinoic acid or derivatives thereof, methotrexate or derivatives thereof, cyclosporin or derivatives thereof, palladium and/or ruthenium or derivatives thereof, immunosuppressors, anti-inflammatory agents, phototherapeutics and cell hyperproliferation modulators.
5. Formulations as claimed in claim 4 containing 0.01 to 20% of resveratrol and/or derivatives thereof.
6. Formulations as claimed in claim 5 containing 1 to 5% of resveratrol and/or derivatives thereof.
7. Formulations as claimed in claims 4 to 6, wherein resveratrol derivatives are selected from the esters and glycosides thereof, and 3'-oxyresveratrol.
8. Formulations as claimed in claims 4 to 7 in the form of gel, creams or ointments.

5

10

15

20

25

30

35


40

45

50

55

THIS PAGE BLANK (USPTO)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 138 323 A3**

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
24.10.2001 Bulletin 2001/43

(43) Date of publication A2:
04.10.2001 Bulletin 2001/40

(21) Application number: 01106638.8

(22) Date of filing: 16.03.2001

(51) Int Cl.7: **A61K 31/047**, A61K 9/06,
A61P 17/00, A61P 17/06,
A61P 17/10, A61K 31/59
// (A61K31/59, 31:047)

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 24.03.2000 IT MI000630

(71) Applicants:
• **D.B.P. (Development Biotechnological Processes) di Rossi Valentina e C. s.n.c.**
83100 Avellino (IT)
• **Nuova ICT s.r.l.**
26845 Codogno (Lodi) (IT)

(72) Inventors:
• **Pelliccia, Maria Teresa**
83100 Avellino (IT)
• **Giannella, Attilio**
26845 Codogno (Lodi) (IT)
• **Giannella, Jenny**
26845 Codogno (Lodi) (IT)

(74) Representative: **Minoja, Fabrizio, Dr.**
Bianchetti Bracco Minoja S.r.l.
Via Rossini, 8
20122 Milano (IT)

(54) **Resveratrol for the treatment of exfoliative eczema, acne or psoriasis**

(57) The use of resveratrol (3,4',5-trihydroxy-trans-stilbene) and derivatives thereof, for the preparation of medicaments for the treatment of exfoliative eczema, acne and psoriasis, topical pharmaceutical formulations containing resveratrol or derivatives thereof in combination with other active principles. Treatment consists in topical administrations of resveratrol at concentrations

of 0.01 to 20%, in the form of lotions, creams or ointments, optionally in combination with other active principles such as melatonin, vitamins D, E and A and derivatives thereof, hormones, vegetable and/or animal extracts. Contrary to current therapies, the use of resveratrol has neither systemic nor topical effects during and after therapy.

EP 1 138 323 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 01 10 6638

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X, D	WO 99 59561 A (HENSLEY KENNETH L ; FLOYD ROBERT A (US); OKLAHOMA MED RES FOUND (US) 25 November 1999 (1999-11-25) * page 5, line 2 - line 7 *	1, 3	A61K31/047 A61K9/06 A61P17/00 A61P17/06 A61P17/10 A61K31/59 /(A61K31/59, A61K31:047)
X	FR 2 777 184 A (OREAL) 15 October 1999 (1999-10-15) * page 4, line 19 - line 23 * * page 6, line 34 - page 7, line 6 *	1, 2	
X	US 5 935 596 A (CROTTY BRIAN ANDREW ET AL) 10 August 1999 (1999-08-10) * column 2, line 38 - line 44 * * column 3, line 45 *	1	
X	WO 99 04747 A (UNILEVER PLC ; UNILEVER NV (NL)) 4 February 1999 (1999-02-04) * example 11; table 5A *	4-6, 8	
X	EP 0 904 774 A (PFIZER PROD INC) 31 March 1999 (1999-03-31) * page 2, line 55 - line 56 * * page 10, line 9 - line 11 *	4	TECHNICAL FIELDS SEARCHED (Int.Cl.7) A61K A61P
X	PATENT ABSTRACTS OF JAPAN vol. 1998, no. 04, 31 March 1998 (1998-03-31) & JP 09 328410 A (YUSHIRO CHEM IND CO LTD; MITSUBA BOEKI KK), 22 December 1997 (1997-12-22) * abstract *	4-6	
E	WO 01 30336 A (LIN SHENGZHAO ; OUALI AOMAR (CA); PHARMASCIENCE (CA); BARILLAS KARL) 3 May 2001 (2001-05-03) * page 5, line 24 - line 27 * * page 6, line 27 - line 31 *	1, 3	
-/--			
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 28 August 2001	Examiner Pilling, S
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.82 (10-01-01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 10 6638

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
E	WO 01 43705 A (JOHNSON & JOHNSON CONSUMER) 21 June 2001 (2001-06-21) * examples 1-3 *	1-6,8	
E	WO 01 30314 A (UNILEVER PLC ; LEVER HINDUSTAN LTD (IN); UNILEVER NV (NL)) 3 May 2001 (2001-05-03) * examples 4-9 *	4-6,8	
P,X	WO 00 38620 A (CASPER ROBERT F ; TENENBAUM HOWARD CHARLES (CA)) 6 July 2000 (2000-07-06) * claims 1,4,5 *	4	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Place of search MUNICH		Date of completion of the search 28 August 2001	Examiner Pilling, S
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1500 01.02 (7/94-C01)

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 01 10 6638

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-08-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9959561 A	25-11-1999	AU 4084599 A	06-12-1999
FR 2777184 A	15-10-1999	EP 0953345 A	03-11-1999
		JP 11322561 A	24-11-1999
US 5935596 A	10-08-1999	US 5985300 A	16-11-1999
		AU 725041 B	05-10-2000
		AU 6729298 A	20-10-1998
		AU 731691 B	05-04-2001
		AU 6830898 A	20-10-1998
		AU 7041798 A	20-10-1998
		BR 9808271 A	16-05-2000
		BR 9808272 A	16-05-2000
		BR 9808397 A	23-05-2000
		CN 1255847 T	07-06-2000
		CN 1257420 T	21-06-2000
		CN 1258216 T	28-06-2000
		WO 9842302 A	01-10-1998
		WO 9842303 A	01-10-1998
		WO 9842304 A	01-10-1998
		EP 0971684 A	19-01-2000
		EP 0969806 A	12-01-2000
		EP 0969808 A	12-01-2000
		HU 0001934 A	28-12-2000
		PL 335763 A	22-05-2000
		PL 335764 A	22-05-2000
		PL 335816 A	22-05-2000
		US 5993838 A	30-11-1999
		US 5968537 A	19-10-1999
		HU 0001514 A	28-09-2000
WO 9904747 A	04-02-1999	AU 730825 B	15-03-2001
		AU 8858498 A	16-02-1999
		BR 9810810 A	12-09-2000
		EP 0980235 A	23-02-2000
		PL 338451 A	06-11-2000
		US 6270780 B	07-08-2001
EP 0904774 A	31-03-1999	AP 857 A	11-07-2000
		AU 735716 B	12-07-2001
		AU 8994698 A	12-04-1999
		BG 104247 A	30-11-2000
		BR 9803596 A	25-04-2000
		CA 2247748 A	23-03-1999
		CN 1270509 T	18-10-2000
		HR 20000168 A	31-08-2000

EPO FORM P0439

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 10 6638

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-08-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0904774 A		HU 0003743 A	28-04-2001
		WO 9915148 A	01-04-1999
		JP 11152203 A	08-06-1999
		NO 20001473 A	22-03-2000
		PL 339551 A	18-12-2000
		TR 200000782 T	21-09-2000
		US 6132740 A	17-10-2000
JP 09328410 A	22-12-1997	JP 3053368 B	19-06-2000
WO 0130336 A	03-05-2001	NONE	
WO 0143705 A	21-06-2001	NONE	
WO 0130314 A	03-05-2001	NONE	
WO 0038620 A	06-07-2000	AU 1853000 A	31-07-2000

EPO FORM P0489

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK (USPTO)